🧬 RETATRUTIDE 10MG
 
Advanced Metabolic Research | BIOPEPTIDES
Discover the next generation of metabolic research with Retatrutide.
Retatrutide is an innovative experimental peptide attracting significant scientific interest for its unique interaction with three metabolic hormone receptors: GLP-1, GIP and glucagon.
Its distinctive triple-receptor activity makes it a compelling compound for advanced research into metabolic regulation, energy balance and hormonal signaling.
 
🔬 Key Research Benefits
🧬 Triple-Receptor Activity – Investigated for its interaction with three important metabolic hormone receptors.
🔥 Metabolic Research – Supports scientific investigations into complex metabolic pathways.
⚡ Energy Balance Studies – Research into biological mechanisms regulating energy expenditure.
📊 Advanced Hormonal Signaling – Exploration of GLP-1, GIP and glucagon pathways.
🧪 Glucose Metabolism Research – Investigation of glucose-related hormonal mechanisms.
🏆 Innovative Research Compound – A distinctive peptide for advanced endocrinology and metabolic research.
🧪 Triple-Receptor Research
GLP-1 Receptor – GLP1R
Investigated for its role in glucose regulation, appetite signaling and metabolic homeostasis.
GIP Receptor – GIPR
Relevant to research into glucose-dependent hormonal responses and metabolic regulation.
Glucagon Receptor – GCGR
Studied for its involvement in glucose metabolism, energy regulation and metabolic signaling.
The simultaneous investigation of these three pathways makes Retatrutide particularly interesting for exploring complex metabolic mechanisms.
 
🏆 BIOPEPTIDES Quality
At BIOPEPTIDES, we emphasize analytical quality, product identification and scientific transparency.
🔬 High-purity research compound.
🏆 Professional research compound selection.
Purity must be verified against the analytical report corresponding to the specific batch.
 
📚 Scientific References | REF
REF 1 – Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. The New England Journal of Medicine, 389, 514–526.
REF 2 – Coskun T et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3–14.
REF 3 – Finan B et al. (2015). A rationally designed monomeric peptide triagonist of GLP-1, glucagon, and GIP receptors. Nature Medicine, 21, 27–36.
🧬 BIOPEPTIDES
Advanced Compounds. Innovative Research. Analytical Quality.
Explore advanced research compounds with a focus on scientific transparency, analytical documentation and batch traceability.
For laboratory research purposes only. Not for human or veterinary use.